Phase I study of low-dose hypomethylating agent azacitidine combined with histone deacetylase inhibitor valproic acid in patients with advanced cancers
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2012
At a glance
- Drugs Azacitidine; Valproic acid
- Indications Cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.